Results 221 to 230 of about 543,196 (314)
Studies on reversible dehydrogenase systems [PDF]
David Ezra Green+1 more
openalex +1 more source
Self‐Adjusting Engineered Probiotic for Targeted Tumor Colonization and Local Therapeutics Delivery
Zou et al. developed an engineered strain of Escherichia coli Nissle 1917 with precise targeting abilities for colonization and on‐demand payload release. The engineered probiotic survives and embolizes tumors only in the presence of more than 5 mM L‐lactate. Furthermore, the introduction of an α‐hemolysin circuit enhances its anti‐tumor effect.
Zhen‐Ping Zou+8 more
wiley +1 more source
A type of polydopamine (PDA) nanogel decorated adhesive and responsive hierarchical microcarriers for ALA delivery and deafness prevention. PDA@microcarriers can protect the encapsulated drugs from external disturbances and prolong their retention time in the inner ear.
Hong Chen+8 more
wiley +1 more source
A reconfigurable microneedle electrode array integrated system is developed for minimally invasive and transdermal monitoring of subcutaneous electromyography, reactive oxygen species, and pH values. By assembling discrete thumbtack‐shaped microneedles into an array, the system enables multi‐parameter detection with single‐microneedle resolution.
Zhengjie Liu+12 more
wiley +1 more source
Histochemical study of 3 dehydrogenase systems in human tumors [PDF]
Benito Monis+2 more
openalex +1 more source
Schematic diagram showing the potential mechanism of bigelovin on the activation of NLRP3 inflammasome Bigelovin may inhibit activated protein C kinase 1 (RACK1) by directly binding with cys168 of RACK1. Bigelovin thus prevents oligomerization of NLRP3 (NLRP3 active conformation) and subsequent assembly of NLRP3 inflammasome, blocking the activation of
Jian Cui+17 more
wiley +1 more source
These findings elucidate the innovative role of HIC1 as a transcriptional activator in GC, driving the initiation of pyroptosis and enhancing CD8+ T cell infiltration, which has certain novelty and creative significance. Collectively, targeting HIC1 can present an appealing immunotherapeutic strategy to improve outcomes in GC patients.
Mengjie Kang+4 more
wiley +1 more source